Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TNF | P01375 | 5/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 1/20 | 0.43 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.43 |
| ▸ | PSMB5 | P28074 | 6/20 | 0.39 |
| ▸ | PSMB2 | P49721 | 6/20 | 0.39 |
| ▸ | PSMB1 | P20618 | 5/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 1/20 | 0.38 |
| ▸ | MTNR1B | P49286 | 1/20 | 0.38 |
| ▸ | MEN1 | O00255 | 2/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CREBBP | Q92793 | 1/20 | 0.36 |
| ▸ | GSK3B | P49841 | 1/20 | 0.36 |
| ▸ | P2RX7 | Q99572 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16328854 | 0.87 | TNF (0.53) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL3768022 | 0.81 | TNF (0.46) | TNFLMNAMAPTCYP2C9MEN1 | |
| SCHEMBL25219017 | 0.81 | TNF (0.43) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL25422253 | 0.79 | TNF (0.45) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL29379768 | 0.79 | TNF (0.45) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL30186329 | 0.78 | TNF (0.43) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL3770428 | 0.78 | TNF (0.46) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL16431670 | 0.78 | TNF (0.43) | TNFLMNAMAPTCYP2C9PSMB5 | |
| SCHEMBL23946037 | 0.78 | LMNA (0.54) | TNFLMNAMAPTCYP2C9ALDH1A1 | |
| SCHEMBL21069700 | 0.78 | ALDH1A1 (0.58) | TNFLMNAMAPTCYP2C9PSMB5 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | KYMERA THERAPEUTICS, INC. (US) | 2022-06-07 | — | — | US | disclosed |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | KYMERA THERAPEUTICS, INC. | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11352350-B2 | IRAK degraders and uses thereof | IRAK2, IRAK3, IRAK1 | TNF 172/4885LMNA 1656/4885MAPT 2459/4885 |
| US-20210323952-A1 | IRAK DEGRADERS AND USES THEREOF | IRAK2, IRAK3, IRAK1 | TNF 172/4885LMNA 1656/4885MAPT 2459/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.